CompletedNCT00237939

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

This study evaluated the effectiveness of Aripiprazole for people with schizophrenia.

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

This study evaluated the effectiveness of Aripiprazole for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Antwerp and 19 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateSeptember 2002

Recruitment status: Completed
Enrollment listed in the registry: 1,200
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: France, Belgium, Netherlands, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT00237939
Official title: Show the full official title
A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)

Completed

Antwerp, Belgium · Brussels, Belgium · Diest, Belgium

17 more locations

FAQ

What did researchers investigate?

This study evaluated the effectiveness of Aripiprazole for people with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.